OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• RAS oncogenic pathway activation, often via RAS gene mutations, is prevalent in human cancers.
• Reversible ubiquitination of RAS GTPases critically influences their activity, implicating related enzymes in cancer development.

Purpose of the Study:

• To identify enzymes regulating RAS ubiquitination.
• To investigate the role of OTUB1 in RAS regulation and its contribution to tumorigenesis.

Main Methods:

• Identification of OTUB1 as a de-ubiquitinase.
• Assessment of OTUB1's effect on RAS ubiquitination and localization.
• Analysis of OTUB1 expression in non-small-cell lung carcinoma (NSCLC) patient samples.

Main Results:

• OTUB1 was identified as a negative regulator of RAS mono- and di-ubiquitination.
• OTUB1 inhibits RAS ubiquitination independently of its catalytic activity, leading to RAS sequestration on the plasma membrane.
• OTUB1 overexpression promotes RAS activation and tumorigenesis in wild-type RAS cells.
• Elevated OTUB1 expression in KRAS wild-type NSCLC correlates with increased ERK1/2 phosphorylation, high Ki67 index, and reduced patient survival.

Conclusions:

• Dysregulation of RAS ubiquitination is an alternative mechanism for RAS activation in lung cancer.
• OTUB1 acts as a tumor promoter by inhibiting RAS ubiquitination and enhancing RAS activity.
• Targeting OTUB1 or RAS ubiquitination pathways may offer new therapeutic strategies for NSCLC.